Latest stories on VSTM
Verastem Oncology Announces U.S. FDA Fast Track Designation for VS-7375, an Oral and Potential Best-in-Class Investigational KRAS G12D (ON/OFF) Inhibitor for the Treatment of KRAS G12D-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | VSTM Stock News
StockTitan77 · bullishproduct/pr
Verastem Oncology to Present at Jefferies Healthcare Conference | VSTM Stock News
StockTitan50 · neutralgeneral
Verastem Shareholders Back Board, Executive Pay and Plans
TipRanks50 · neutralgeneral
Verastem Oncology Appoints Michael P. Bailey to its Board of Directors | VSTM Stock News
StockTitan53 · neutralgeneral